The in vitro and in vivo data presented at the 2024 International HBV Meeting advance the development of a new approach to treat and cure Hepatitis B virus,” said Daniel Dornbusch, Chief Executive ...
NanoViricides, Inc. (NYSE American.:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal ...